Hyloris Pharmaceuticals S.A. risk profile
70 Stretched several inputs deteriorating together
Measured 21 October 2026 from 0AB6's filed statements. Recomputed nightly.
70 (Stretched), driven by Cash conversion at 100, over 4 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 87 | Acute | Stable | Drawdown from the 52-week high — 47.9% |
| Operating pressure | 55 | Elevated | Stable | Costs outgrowing revenue — +15.4 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.09x |
| Leverage and coverage | 37 | Normal | Stable | Interest cover — -88.36x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for Hyloris Pharmaceuticals S.A.